Cardioxyl Pharmaceuticals has secured $28 million in a Series B financing led by OrbiMed Advisors. New investor Osage University Partners joined OrbiMed and returning investors New Enterprise Associates and The Aurora Funds in the financing.

If you don’t eat your life sciences portfolio, you can’t have any Sequoia for dessert! As LPs continue to digest medical technology VC investments, GPs are left hungry for more capital.

Sera Prognostics Inc., a company developing tests to diagnose preterm birth and other pregnancy complications, has raised $19.3 million from a slew of investors including InterWest Partners, Domain Associates, Catalyst Health Ventures, UpStart Life Sciences Capital and Osage University Partners. The Series A financing will help fund clinical trials and the commercial launch of its preterm birth diagnostic test.

Cambridge, Mass.-based MC10 has closed on $12 million in Series B financing led by new investor Braemar Energy Ventures. Existing shareholders North Bridge Venture Partners, Osage University Partners and Terawatt Ventures also contributed to the round. MC10 develops technology designed to transform high-performance electronics into systems that can bend, stretch and wrap into different shapes. The technology is applicable to sports, military and biomedical fields.

Aerie Pharmaceuticals Inc., a biotechnology company focused on medical innovations in ophthalmology, has closed $30 million in Series B financing. Clarus Ventures and Sofinnova Ventures co-led the round, with participation from Osage University Partners and existing investors Alta Partners and TPG Biotech. Aerie Pharmaceuticals has offices in Research Triangle Park, N.C. and in Bridgewater, N.J.

Osage University Partners said Thursday that it has closed its first fund, Osage University Partners I, at $100 million. The VC fund is affiliated with universities to make direct investments in startup companies.